


# PRODUCT INFORMATION



## Trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt)

Item No. 9002107

**Formal Name:** N-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-2-(4-((2,6-diaminopyrimidin-4-yl)methyl)-2,6-dimethoxyphenoxy)acetamide tris(2,2,2-trifluoroacetate)  
**MF:** C<sub>23</sub>H<sub>36</sub>N<sub>6</sub>O<sub>7</sub> • 3CF<sub>3</sub>COOH  
**FW:** 850.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 210 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. Trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt) in these solvents is approximately 10, 15, and 20 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of trimethoprim-PEG<sub>3</sub>-amine (trifluoroacetate salt) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Trimethoprim-PEG<sub>3</sub>-amine is a conjugated form of trimethoprim linked with polyethylene glycol (PEG) amine. The addition of PEG to drugs can provide greater solubility, longer duration of exposure, and the potential to overcome resistance associated with the drug.<sup>1</sup>

### Reference

1. Zamboni, W.C. Concept and clinical evaluation of carrier-mediated anticancer agents. *Oncologist* **13**(3), 248-260 (2008).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/11/2025

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)